Taysha Gene Therapies, Inc. (TSHA) Income Statement
TSHA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTSHA revenue and net income
Where TSHA's revenue goes
2025Each bar shows an amount and its share of revenue. TSHA kept −1,115.3% of revenue as net income.
TSHA profit margins
TSHA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +17.3% | +57.5% | — | — |
| Gross profit | +17.3% | +766.9% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TSHA quarterly EPS vs estimates
Taysha Gene Therapies beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.14).
TSHA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | $0 | $0 | $0 |
| Cost of revenue | $1.1M | $1.2M | $1.4M | $2.5M | $492,000 | $9,000 | — |
| Gross profit | $9.8M | $8.3M | $15.5M | $14,999 | −$492,000 | −$9,000 | — |
| Research & development | $86.4M | $66.0M | $56.8M | $91.2M | $131.9M | $31.9M | $987,000 |
| Sales, general & admin | $33.9M | $29.0M | $31.4M | $37.4M | $41.3M | $11.1M | $512,000 |
| Total operating expenses | $120.3M | $99.8M | $87.9M | $126.0M | $173.3M | $43.0M | $1.1M |
| Operating income | −$110.5M | −$91.5M | −$72.4M | −$126.0M | −$173.3M | −$43.0M | −$1.1M |
| Interest income | $9.2M | $6.9M | $1.9M | $249,000 | $172,000 | $49,000 | — |
| Interest expense | $63,000 | $102,000 | $5.0M | $3.8M | $1.4M | $28,000 | $0 |
| Income before taxes | −$109.0M | −$89.3M | −$111.6M | −$166.0M | −$174.5M | −$60.0M | −$1.1M |
| Income taxes | — | −$89.3M | $1.2M | $3.6M | $936,000 | −$17.0M | −$4.5M |
| Net income | −$109.0M | −$89.3M | −$111.6M | −$166.0M | −$174.5M | −$43.0M | −$1.1M |
| EBITDA | −$107.8M | −$88.0M | −$105.2M | −$161.0M | −$172.6M | −$60.0M | −$1.1M |
| EPS (diluted) | −$0.32 | −$0.33 | −$0.67 | −$3.78 | −$4.63 | −$3.60 | −$0.07 |
| Gross margin | 100.0% | 100.0% | 100.0% | 0.6% | — | — | — |
| Operating margin | −1,130.6% | −1,097.6% | −468.8% | −5,037.1% | — | — | — |
| Net margin | −1,115.3% | −1,071.6% | −722.1% | −6,635.3% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $5.5M | $0 | $2.0M | $2.3M | $2.0M | $1.8M | $1.1M | $3.4M | $3.6M | $4.7M |
| Cost of revenue | — | $295,000 | $299,000 | $286,000 | $277,000 | $0 | −$625,000 | $0 | $300,000 | $325,000 | $366,000 | $331,000 |
| Gross profit | — | −$295,000 | $5.2M | −$286,000 | $2.0M | $2.3M | $2.0M | $1.8M | $1.1M | $3.4M | $3.6M | $4.4M |
| Research & development | $38.6M | $33.8M | $24.7M | $25.5M | $20.1M | $15.6M | $15.3M | $14.9M | $15.1M | $20.7M | $12.7M | $11.8M |
| Sales, general & admin | $12.1M | $9.7M | $8.8M | $8.3M | $8.6M | $8.2M | $7.0M | $7.9M | $7.6M | $7.4M | $7.1M | $8.6M |
| Total operating expenses | $47.3M | $43.2M | $33.5M | $33.7M | $28.7M | $23.7M | $22.0M | $27.7M | $22.4M | $27.7M | $19.9M | $20.0M |
| Operating income | −$47.3M | −$43.5M | −$28.3M | −$34.0M | −$26.8M | −$21.4M | −$19.9M | −$25.9M | −$21.3M | −$24.3M | −$16.2M | −$15.6M |
| Interest income | $2.3M | $2.6M | $2.9M | $3.2M | $1.9M | $1.3M | $1.7M | $2.1M | $1.4M | $1.7M | $1.9M | $1.1M |
| Interest expense | $6,000 | $9,000 | $12,000 | $15,000 | $17,000 | $19,000 | $22,000 | $24,000 | $27,000 | $29,000 | $713,000 | $1.5M |
| Income before taxes | −$46.6M | −$42.4M | −$27.9M | −$32.7M | −$26.9M | −$21.5M | −$18.8M | −$25.5M | −$20.9M | −$24.1M | $47.7M | −$117.1M |
| Income taxes | — | — | — | — | — | — | −$281,724 | — | — | $281,724 | −$3.5M | −$331,000 |
| Net income | −$46.6M | −$42.4M | −$27.9M | −$32.7M | −$26.9M | −$21.5M | −$18.8M | −$25.5M | −$20.9M | −$24.1M | $47.7M | −$117.1M |
| EBITDA | −$46.3M | −$42.1M | −$28.0M | −$32.4M | −$26.6M | −$21.2M | −$18.5M | −$25.2M | −$20.6M | −$23.7M | $48.8M | −$115.3M |
| EPS (diluted) | −$0.13 | −$0.11 | −$0.07 | −$0.09 | −$0.08 | −$0.08 | −$0.07 | −$0.07 | −$0.09 | −$0.10 | $0.92 | −$0.93 |
| Gross margin | — | — | 94.5% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| Operating margin | — | — | −516.0% | — | −1,347.1% | −930.5% | −985.8% | −1,448.4% | −1,915.4% | −713.3% | −450.8% | −329.4% |
| Net margin | — | — | −507.8% | — | −1,353.6% | −935.2% | −929.0% | −1,427.5% | −1,882.0% | −705.4% | 1,324.7% | −2,467.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TSHA's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TSHA financial results
In fiscal year 2025 (ended December 31, 2025), Taysha Gene Therapies reported revenue of $9.8 million, up 17.3% from the year before. It had a net loss of $109.0 million, a net profit margin of −1,115.3%. Diluted earnings per share came to −$0.32.
See the TSHA stock overview for the latest quote and news, or the TSHA chart for price history and technical indicators.
TSHA income statement FAQ
What is Taysha Gene Therapies's annual revenue?
Taysha Gene Therapies reported total revenue of $9.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 17.3% from $8.3 million the previous year.
Is Taysha Gene Therapies profitable?
No. Taysha Gene Therapies reported a net loss of $109.0 million in fiscal 2025, a net profit margin of −1,115.3%; its operating margin was −1,130.6%.
What is Taysha Gene Therapies's gross margin?
Taysha Gene Therapies's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Taysha Gene Therapies kept $100 after the direct cost of its products and services.
How much does Taysha Gene Therapies spend on research and development?
Taysha Gene Therapies spent $86.4 million on research and development in fiscal 2025, 884.1% of revenue.
What are Taysha Gene Therapies's earnings per share?
Taysha Gene Therapies earned $-0.32 per diluted share in fiscal 2025, compared with $-0.33 a year earlier.
When will Taysha Gene Therapies report its next earnings?
Taysha Gene Therapies is expected to report results for the quarter ending September 30, 2026 on November 3, 2026.
When does Taysha Gene Therapies's fiscal year end?
Taysha Gene Therapies's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.